SCHEMBL30205995

SCHEMBL30205995

Fc1cc(CN2C[C@H]3C[C@@H]2CO3)ccc1Br

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.40
TLR7 Q9NYK1 2/20 0.39
PDE1B Q01064 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
METTL3 Q86U44 1/20 0.35
IDH1 O75874 1/20 0.35
CCNC P24863 2/20 0.34
CDK8 P49336 2/20 0.34
PDE10A Q9Y233 2/20 0.34
KMT2A Q03164 1/20 0.34
KDM1A O60341 2/20 0.33
KCNH2 Q12809 2/20 0.33
KDM1B Q8NB78 1/20 0.33
NPC1 O15118 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30206158 1.00 BRAF (0.40) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL1929059 0.80 JAK2 (0.43) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL30206180 0.77 TLR7 (0.33) TLR7PDE1BJAK2JAK1PDE10A
SCHEMBL9953012 0.75 TLR7 (0.45) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL15312373 0.75 TLR7 (0.45) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL22425610 0.75 TLR7 (0.43) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL15324898 0.75 TLR7 (0.43) BRAFTLR7PDE1BJAK2JAK1
SCHEMBL30206260 0.74 SOS1 (0.40) IDH1KDM1AKCNH2KDM1B
SCHEMBL15317724 0.71 TLR7 (0.41) TLR7PDE1BJAK2JAK1CCNC
SCHEMBL14857043 0.71 DGKZ (0.41) TLR7PDE1BJAK2JAK1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 BRAF 305/4885TLR7 4346/4885PDE1B 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.